期刊文献+

苯磺酸左旋氨氯地平联合雷米普利治疗肾性高血压患者的疗效和安全性 被引量:10

Efficacy and safety of levamlodipine combined with ramipril in patients with renal hypertension
下载PDF
导出
摘要 目的观察苯磺酸左旋氨氯地平和雷米普利联合用药对肾性高血压患者的疗效和安全性。方法将158例肾性高血压患者随机分成A、B、C三组。A组采用苯磺酸左旋氨氯地平联合雷米普利治疗;B组单用雷米普利治疗;C组单用苯磺酸左旋氨氯地平治疗。分别记录用药前后血压、肾功能、24 h尿蛋白定量及不良反应。结果三组患者一般情况差异无统计学意义(P>0.05);用药12 W后,A组血压及24 h尿蛋白定量下降更明显,差异有统计学意义(P<0.05);A组肾功能改善更明显,但差异无统计学意义(P>0.05);不良反应发生情况的差异无统计学意义(P>0.05)。结论苯磺酸左旋氨氯地平联合雷米普利治疗肾性高血压比单用两药能更好地控制血压、降低24 h尿蛋白水平及改善肾功能,不良反应更少,疗效显著、安全,费用低,值得临床推广。 Objective We observed efficacy and safety of levamlodipine combined with ramipril in patients with renal hypertension. Methods 158 patients with renal hypertension were randomly divided into A,B and C group. The A group used levamlodipine and ramipril to treat hypertension; The B group used ramipril and the C group used levamlodipine to treat hypertension. Record blood pressure, kidney function 24 hours urine protein quantitative and adverse reactions occur before and after medication. Results Three groups of patients generally compare differences had no statistical significance(P〈0.05);The blood pressure and 24 h urine protein quantitative of treatment group fell more obvious after treatment 12 W, and the difference was statistically significant(P〈0.05);Renal function in the treatment group was more obvious, but the difference was not statistically significant(P〉0.05);There was no significant difference in the incidence of adverse reactions(P〉0.05).Conclusion Levamlodipine combined with ramipril treatment of renal hypertension than using ramipril or used levamlodipine alone can better control of blood pressure, reduce 24 hours urine protein level and improve renal function, less adverse reaction, obvious curative effect, safety, was worth of clinical promotion.
机构地区 遂宁市中心医院
出处 《医疗装备》 2016年第5期3-5,共3页 Medical Equipment
基金 2014年遂宁市市级课题基金项目
关键词 苯磺酸左旋氨氯地平 雷米普利 肾性高血压 治疗 levamlodipine ramipril renal hypertension treatment
  • 相关文献

参考文献15

  • 1刘章锁.肾性高血压治疗进展[J].实用医院临床杂志,2008,5(4):22-24. 被引量:17
  • 2刘立刚.硝苯地平控释片和盐酸贝那普利治疗肾性高血压疗效观察[J].中国卫生标准管理,2014,5(2):32-34. 被引量:8
  • 3Syrigos K N, Karapanagiotou E, Boura P, et al. Bevacizumab- induced hypertension: pathogenesis and management[J].Bio Drugs, 2011, 25(3) : 159-169.
  • 4Mancia G, De Backer G, Dominiezak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension(ESH) and of the European society of cardiology(ESC) [J].J Hypertens, 2007, 25(5):1105-1187.
  • 5王海燕.肾脏病学.北京:人民卫生出版社,2012.1463-1470.
  • 6王靖,赵应兰,杨爱芝.重症监护病房控制多重耐药菌感染的体会[J].护士进修杂志,2010,25(9):860-861. 被引量:70
  • 7Dussol B, Morange S, Loundoun A, et al. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients[J]. Nephrol Dial Transplant, 2006, 21(8) : 2120- 2126.
  • 8Yang YL, Yu LT, Wu ZT, et al. Synergic effects of levamlodipine and bisoprolol on blood pressure reduction and organ protection in spontaneously hypertensive rats[J].CNS Neurosci Ther, 2012,18(6): 471-474.
  • 9Gui H, Guo YF, Liu X, et al. Effects of combination therapy with levamlodipine and bisoprolol on stroke in rats[J].CNS Neurosci Ther, 2013,19(3):178-182.
  • 10刘霖,曹剑,范利,等.阿司匹林联合雷米普利对自发性血压大鼠血小板功能的影响[C]//第二届中国高血压会暨中国医师协会高血压专业委员会年会论文集,2012:40—41.

二级参考文献34

  • 1霍建宏,张文兵.老年高血压患者脉压与左房构型改变的相关研究[J].中国现代医学杂志,2004,14(22):128-129. 被引量:4
  • 2刘英明,朱智明,曹毅,李贤峰,高连如,杨晔,卢才义,王士雯.阻断肾素-血管紧张素系统对高血压患者心房颤动发生危险的影响[J].中国心脏起搏与心电生理杂志,2005,19(4):264-266. 被引量:22
  • 3卢月梅,张阮章,何林,王沙燕,陈升汶.近4年产超广谱β-内酰胺酶肺炎克雷伯菌基因型分布及耐药性变化[J].中华医院感染学杂志,2005,15(10):1090-1093. 被引量:13
  • 4谌贻璞.慢性肾脏病高血压的治疗目标及药物应用[J].临床内科杂志,2005,22(11):726-728. 被引量:26
  • 5[1]Ruilope LM,Salvetti A,Jamerson K,et aL Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study[J].J Am Soc Nephrol,2001,12(2):218-225.
  • 6[2]Maschio G,Alberti D,LocateUi F,et aL Angiotensin-converting enzyme inhibitors and kidney protection:the AIPRI triaL The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group[J].J Cardiovasc Pharmacol,1999,33(suppl 1):S16-20.
  • 7[3]Hou FF,Zhang X,Zhang GH,et al.Efficacy and safety of benazepril for advanced chronic renal insufficiency[J].N Engl J Med,2006,354 (2):131-140.
  • 8[4]Ruggenenti P,Pema A,Gherardi G,et aL Renal function and require-ment for dialysis in chronic nephropathy patients on long-term ramipril:REIN follow-up trial.Gruppo Italiano di Studi Epidemiologici in Nefrolo-gia (GISEN)[J].Lancet,1998,352(9136):1252-1256.
  • 9[5]Parring HH,Lehnert H,Brochner MJ,et aL The effect of irbesartan on the development of diabetic ncphropathy in patients with type 2 diabetes[J].N Engl J Med,2001,345(12):870-878.
  • 10[6]Giancarlo V,Nigel MW.Microalbuminuria reduction with valsartan in patients with type-2 diabetes mellitus:a blood pressure-independent effect[J].Circulation,2002,106(3):672-678.

共引文献139

同被引文献89

引证文献10

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部